Replies to post #165073 on Biotech Values

[iwfal]

XOMA -

Behçet’s is not a strong enough indication to be the centerpiece of the company’s business model.

1) You completely missed my point. --- "Initial indication" "Priming"

2) On a completely separate topic... I would suggest it is odd to say that an orphan indication cannot be a centerpiece.